PE
PETS.US PetMed Express Inc
- Market cap
- USD 20.0M
- P/E
- -
- P/B
- 1.24x
- ROE
- -149.2%
- Dividend yield
- 0.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is PETS.US undervalued?
Graham numberThe Graham number of PetMed Express Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PetMed Express Inc fundamental analysis
No fundamental analysis for PetMed Express Inc yet.
PetMed Express Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PetMed Express Inc
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications,…
Full company profilePetMed Express Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PetMed Express Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 235M | 249M | 274M | 283M | 284M | 304M | 273M | 257M | 274M | 179M | 154M |
| Gross Profit | 76.3M | 79.3M | 97.8M | 95.3M | 81.2M | 84.3M | 75.3M | 71.0M | 77.7M | 40.8M | 42.3M |
| Operating Income | 32.4M | 37.5M | 52.1M | 46.2M | 31.0M | 30.5M | 25.7M | 6.55M | -6.96M | -31.4M | -25.3M |
| EBITDA | 33.2M | 38.9M | 54.3M | 51.3M | 36.2M | 33.0M | 29.8M | 11.0M | 783K | -22.0M | -17.5M |
| Net Income | 20.6M | 23.8M | 37.3M | 37.7M | 25.9M | 23.9M | 21.1M | 5.14M | -7.46M | -57.3M | -25.2M |
| EPS | 1.02 | 1.17 | 1.82 | 1.84 | 1.29 | 1.19 | 1.04 | 0.25 | -0.37 | -2.74 | -1.19 |
| Balance Sheet | |||||||||||
| Total Assets | 90.3M | 113M | 135M | 154M | 155M | 187M | 176M | 170M | 170M | 81.2M | 59.4M |
| Total Liabilities | 7.08M | 19.4M | 19.1M | 19.7M | 25.3M | 46.2M | 34.1M | 60.0M | 73.2M | 52.3M | 42.5M |
| Shareholders' Equity | 83.2M | 93.4M | 116M | 135M | 130M | 141M | 142M | 110M | 96.7M | 28.9M | 16.9M |
| Cash & Short-term Investments | 37.6M | 58.7M | 77.9M | 101M | 104M | 119M | 111M | 104M | 55.3M | 21.4M | 11.4M |
| Total Debt | - | - | - | - | - | - | - | 995K | 1.45M | 535K | 291K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 21.1M | 47.2M | 37.4M | 45.1M | 38.8M | 40.1M | 18.5M | 27.8M | 4.32M | -28.4M | -17.5M |
| Capital Expenditure | 20.1M | 10.6M | 703K | 620K | 2.31M | 2.43M | 1.75M | 5.26M | 4.51M | 4.62M | 2.45M |
| Free Cash Flow | 923K | 36.6M | 36.7M | 44.5M | 36.5M | 37.6M | 16.7M | 22.5M | -194K | -33.0M | -19.9M |
| Ratios | |||||||||||
| ROE | 24.7% | 25.5% | 32.2% | 28.0% | 19.9% | 16.9% | 14.8% | 4.7% | -7.7% | -197.9% | -149.2% |
| ROA | 22.8% | 21.1% | 27.7% | 24.4% | 16.6% | 12.8% | 12.0% | 3.0% | -4.4% | -70.6% | -42.4% |
| Net Profit Margin | 8.8% | 9.6% | 13.6% | 13.3% | 9.1% | 7.9% | 7.7% | 2.0% | -2.7% | -32.0% | -16.4% |
| Debt to Equity | - | - | - | - | - | - | - | 0.01x | 0.02x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PetMed Express Inc dividends
- Dividend yield
- 0.11%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 11, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 21.0K | 0.00 | - |
| 2025 | - | - | - |
| 2024 | USD 12.4M | 0.61 | - |
| 2023 | USD 24.5M | 1.21 | 477.4% |
| 2022 | USD 24.4M | 1.20 | 115.6% |
| 2021 | USD 22.7M | 1.13 | 94.8% |
| 2020 | USD 21.8M | 1.09 | 84.3% |
| 2019 | USD 21.9M | 1.07 | 58.1% |
| 2018 | USD 17.5M | 0.85 | 46.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 959692:319897 on Mar 4, 1999.
Who owns PetMed Express Inc
- Insiders 18.06%
- Institutions 35.17%
- Public & others 46.77%
- Shares outstanding 22.2M
- Free float 13.9M
Top funds holding PETS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 603K | 2.72% | 0.00% | Sep 2026 |
| Pinnacle Value | 311K | 1.41% | +23.45% | Jun 2026 |
| Federated Hermes MDT Small Cap Value A | 117K | 0.53% | 0.00% | Sep 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 95.2K | 0.43% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 66.2K | 0.30% | +322.82% | Sep 2026 |
| T. Rowe Price Total Equity Market Idx | 48.9K | 0.22% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 46.8K | 0.21% | 0.00% | Oct 2026 |
| T. Rowe Price Extended Equity Market Idx | 38.5K | 0.17% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 35.7K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 28.9K | 0.13% | 0.00% | Sep 2026 |
| Bridgeway Omni Small-Cap Value N | 25.0K | 0.11% | 0.00% | Jun 2026 |
| Vanguard Balanced Index Inv | 13.5K | 0.06% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 9.74K | 0.04% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 8.12K | 0.04% | 0.00% | Sep 2026 |
| JNL/DFA US Small Cap A | 4.95K | 0.02% | 0.00% | Sep 2026 |
| AST Small-Cap Equity Portfolio | 4.41K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding PETS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Renaissance Technologies Corp | 1.07M | 4.84% | -5.36% | Sep 2026 |
| Vanguard Capital Management, LLC | 827K | 3.74% | -0.49% | Jun 2026 |
| BlackRock Inc | 568K | 2.57% | +3.01% | Jun 2026 |
| Federated Hermes Inc | 212K | 0.96% | -68.18% | Jun 2026 |
| Geode Capital Management, LLC | 204K | 0.92% | -7.88% | Jun 2026 |
| Steel Partners Holdings LP | 194K | 0.88% | 0.00% | Jun 2026 |
| UBS Group AG | 138K | 0.63% | -40.80% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 130K | 0.59% | +8.23% | Jun 2026 |
| Bridgeway Capital Management, LLC | 121K | 0.55% | -8.80% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 110K | 0.50% | +0.70% | Jun 2026 |
| State Street Corp | 105K | 0.48% | 0.00% | Jun 2026 |
| Formidable Asset Management LLC | 85.6K | 0.39% | -18.68% | Jun 2026 |
| Curated Wealth Partners LLC | 85.0K | 0.38% | 0.00% | Jun 2026 |
| Empowered Funds, LLC | 82.3K | 0.37% | +9.76% | Jun 2026 |
| Tudor Investment Corp Et AL | 81.4K | 0.37% | 0.00% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 79.5K | 0.36% | -37.29% | Jun 2026 |
| Citadel Advisors Llc | 74.1K | 0.33% | -15.66% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 60.4K | 0.27% | 0.00% | Sep 2026 |
| UMB Bank NA | 60.0K | 0.27% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 47.7K | 0.22% | 0.00% | Jun 2026 |
PetMed Express Inc company profile
- Company name
- PetMed Express Inc
- Ticker
- PETS.US
- Exchange
- USA Stocks
- Listed since
- Apr 26, 1999
- Sector
- Healthcare
- Industry
- Specialty Retail
- Employees
- 189
- Fiscal year end
- March
- Address
- 420 South Congress Avenue, Delray Beach, FL, United States, 33445
- Phone
- 561 526 4444
- Website
- 1800petmeds.com
About PetMed Express Inc
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.
PetMed Express Inc management
8- Mr. Douglas KrulikChief Accounting Officer, Principal Acc. Off., Interim Principal Financial Officer & Treasurer · born 1970
- Ms. Leslie C. G. CampbellStrategic Advisor · born 1958
- Mr. Jeffrey Allen WillardCEO, President & Director · born 1970
- Mr. Andrew ParryChief Technology Officer
- Mr. Robert LawskyCorporate Secretary & General Counsel
- Ms. Jacqueline SmithVice President of People
- Ms. Caroline ConeglianoChief Growth Officer
- Wendy ZalaiCorporate Controller & Corporate Secretary